Screener
Aclaris Therapeutics ACRS Single Reportable — Nonoperating Income Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| (In thousands) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Other research and development(2) | 1,398 | 1,462 | 3,297 | 2,962 |
| Total research and development | 18,066 | 11,449 | 33,723 | 23,033 |
| General and administrative(3) | 6,048 | 5,386 | 12,791 | 11,525 |
| Licensing | 1,235 | 1,335 | 2,628 | 2,345 |
| Revaluation of contingent consideration | 300 | 1,500 | 300 | 1,800 |
| Segment operating loss | $(24,238) | $(18,408) | $(46,430) | $(36,492) |
| Other income | 2,733 | 2,979 | 5,101 | 5,978 |
| Segment loss before income taxes | $(21,505) | $(15,429) | $(41,329) | $(30,514) |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's single reportable — nonoperating income expense?
- Aclaris Therapeutics (ACRS) reported single reportable — nonoperating income expense of $2.73M in Q2 2026.
- How has Aclaris Therapeutics's single reportable — nonoperating income expense changed year-over-year?
- Aclaris Therapeutics's single reportable — nonoperating income expense decreased by 8.3% year-over-year, from $2.98M to $2.73M.
- What does single reportable — nonoperating income expense mean?
- This metric represents the net financial impact of activities outside the primary business operations of the segment, such as interest income, interest expense, or gains and losses from investments. It provides insight into the segment's financial health independent of its core research and development or service delivery activities. Monitoring this helps investors distinguish between operational performance and secondary financial results.
Ask your AI about Aclaris Therapeutics's single reportable — nonoperating income expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude